# Siegfried Janz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3463009/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 115 papers | 3,649 citations | 147801 31 h-index | 144013 57 g-index |
| 117 all docs | 117 docs citations | 117 times ranked | 4789 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Multicolour spectral karyotyping of mouse chromosomes. Nature Genetics, 1996, 14, 312-315. | 21.4 | 307 |
| 2 | Regulation of AID expression in the immune response. Journal of Experimental Medicine, 2007, 204, 1145-1156. | 8.5 | 229 |
| 3 | Burkitt Lymphoma in the Mouse. Journal of Experimental Medicine, 2000, 192, 1183-1190. | 8.5 | 195 |
| 4 | Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Molecular Cancer, 2007, 6, 71. | 19.2 | 155 |
| 5 | Lymphomaâ€•and leukemiaâ€associated chromosomal translocations in healthy individuals. Genes Chromosomes and Cancer, 2003, 36, 211-223. | 2.8 | 136 |
| 6 | IL-6 transgenic mouse model for extraosseous plasmacytoma. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 1509-1514. | 7.1 | 123 |
| 7 | HHV-8â€“encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood, 2012, 119, 5173-5181. | 1.4 | 110 |
| 8 | Insertion of c-Myc into Igh Induces B-Cell and Plasma-Cell Neoplasms in Mice. Cancer Research, 2005, 65, 1306-1315. | 0.9 | 105 |
| 9 | Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies. Clinical Cancer Research, 2011, 17, 7313-7323. | 7.0 | 101 |
| 10 | NF-ÎºB/STAT3/PI3K signaling crosstalk in iMycEÎ¼ B lymphoma. Molecular Cancer, 2010, 9, 97. | 19.2 | 99 |
| 11 | Myc translocations in B cell and plasma cell neoplasms. DNA Repair, 2006, 5, 1213-1224. | 2.8 | 92 |
| 12 | Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice. Journal of Clinical Investigation, 2004, 113, 1763-1773. | 8.2 | 84 |
| 13 | Prevalence and frequency of circulating t(14;18)â€MBR translocation carrying cells in healthy individuals. International Journal of Cancer, 2009, 124, 958-963. | 5.1 | 82 |
| 14 | HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. Journal of Hematology and Oncology, 2021, 14, 54. | 17.0 | 75 |
| 15 | Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice. Journal of Clinical Investigation, 2004, 113, 1763-1773. | 8.2 | 70 |
| 16 | Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model. Molecular Cancer Therapeutics, 2013, 12, 1140-1150. | 4.1 | 68 |
| 17 | Bruton Tyrosine Kinase Is a Therapeutic Target in Stem-like Cells from Multiple Myeloma. Cancer Research, 2015, 75, 594-604. | 0.9 | 65 |
| 18 | B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18956-18960. | 7.1 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunologic Research, 2014, 59, 188-202. | 2.9 | 57 |
| 20 | Piperlongumine inhibits proliferation and survival of Burkitt lymphoma in vitro. Leukemia Research, 2013, 37, 146-154. | 0.8 | 56 |
| 21 | NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. Oncotarget, 2014, 5, 11986-11997. | 1.8 | 54 |
| 22 | IL-6 and MYC collaborate in plasma cell tumor formation in mice. Blood, 2010, 115, 1746-1754. | 1.4 | 49 |
| 23 | COMBO-FISH: specific labeling of nondenatured chromatin targets by computer-selected DNA oligonucleotide probe combinations. BioTechniques, 2003, 35, 564-577. | 1.8 | 47 |
| 24 | Deletional remodeling of c-myc-deregulating chromosomal translocations. Oncogene, 1997, 15, 2369-2377. | 5.9 | 46 |
| 25 | AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements. Journal of Experimental Medicine, 2007, 204, 2989-3001. | 8.5 | 45 |
| 26 | A Transgenic Mouse Model of Plasma Cell Malignancy Shows Phenotypic, Cytogenetic, and Gene Expression Heterogeneity Similar to Human Multiple Myeloma. Cancer Research, 2007, 67, 4069-4078. | 0.9 | 43 |
| 27 | Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?. Oncotarget, 2015, 6, 40496-40506. | 1.8 | 42 |
| 28 | PIAS1 Promotes Lymphomagenesis through MYC Upregulation. Cell Reports, 2016, 15, 2266-2278. | 6.4 | 39 |
| 29 | Deregulated expression of the Myc cellular oncogene drives development of mouse â€œBurkitt-likeâ€• lymphomas from naive B cells. Blood, 2005, 105, 2135-2137. | 1.4 | 38 |
| 30 | Selenium Deficiency Abrogates Inflammation-Dependent Plasma Cell Tumors in Mice. Cancer Research, 2004, 64, 2910-2917. | 0.9 | 35 |
| 31 | Distribution of t(14;18)-positive, putative lymphoma precursor cells among B-cell subsets in healthy individuals. British Journal of Haematology, 2007, 138, 349-353. | 2.5 | 33 |
| 32 | Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma. Journal of the National Cancer Institute, 2020, 112, 507-515. | 6.3 | 33 |
| 33 | CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. Molecular Cancer, 2021, 20, 84. | 19.2 | 33 |
| 34 | RIP1 Cleavage in the Kinase Domain Regulates TRAIL-Induced NF-Îºb Activation and Lymphoma Survival. Molecular and Cellular Biology, 2015, 35, 3324-3338. | 2.3 | 28 |
| 35 | Characterization of ARF-BP1/HUWE1 Interactions with CTCF, MYC, ARF and p53 in MYC-Driven B Cell Neoplasms. International Journal of Molecular Sciences, 2012, 13, 6204-6219. | 4.1 | 27 |
| 36 | NAT10 promotes cell proliferation by acetylating CEP170 mRNA to enhance translation efficiency in multiple myeloma. Acta Pharmaceutica Sinica B, 2022, 12, 3313-3325. | 12.0 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations. Oncogene, 2002, 21, 7235-7240. | 5.9 | 26 |
| 38 | Anaplastic, Plasmablastic, and Plasmacytic Plasmacytomas of Mice: Relationships to Human Plasma Cell Neoplasms and Late-Stage Differentiation of Normal B Cells. Cancer Research, 2007, 67, 2439-2447. | 0.9 | 26 |
| 39 | Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells. Biochemical and Biophysical Research Communications, 2013, 436, 660-665. | 2.1 | 26 |
| 40 | BCL2 accelerates inflammation-induced BALB/c plasmacytomas and promotes novel tumors with coexisting T(12;15) and T(6;15) translocations. Cancer Research, 2003, 63, 8656-63. | 0.9 | 26 |
| 41 | Conformational differences in the 3-D nanostructure of the immunoglobulin heavy-chain locus, a hotspot of chromosomal translocations in B lymphocytes. Cancer Genetics and Cytogenetics, 2001, 127, 168-173. | 1.0 | 24 |
| 42 | Insertion of Myc into Igh Accelerates Peritoneal Plasmacytomas in Mice. Cancer Research, 2005, 65, 7644-7652. | 0.9 | 24 |
| 43 | Deregulation of c-Myc Confers Distinct Survival Requirements for Memory B Cells, Plasma Cells, and Their Progenitors. Journal of Immunology, 2008, 181, 7537-7549. | 0.8 | 24 |
| 44 | Elevated presence of retrotransposons at sites of DNA double strand break repair in mouse models of metabolic oxidative stress and MYC-induced lymphoma. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 548, 117-125. | 1.0 | 23 |
| 45 | t(14;18) Translocations and Risk of Follicular Lymphoma. Journal of the National Cancer Institute Monographs, 2008, 2008, 48-51. | 2.1 | 23 |
| 46 | WaldenstrÃ¶m Macroglobulinemia: Clinical and Immunological Aspects, Natural History, Cell of Origin, and Emerging Mouse Models. ISRN Hematology, 2013, 2013, 1-25. | 1.6 | 23 |
| 47 | Modulation of the H2O2-induced SOS response in escherichia coli PQ300 by amino acids, metal chelators, antioxidants, and scavengers of reactive oxygen species. Environmental and Molecular Mutagenesis, 1993, 22, 157-163. | 2.2 | 22 |
| 48 | Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. Blood Cancer Journal, 2022, 12, 34. | 6.2 | 22 |
| 49 | Forkhead Box M1 Regulates Quiescence-Associated Radioresistance of Human Head and Neck Squamous Carcinoma Cells. Radiation Research, 2014, 182, 420. | 1.5 | 21 |
| 50 | Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer, 2018, 18, 1152. | 2.6 | 21 |
| 51 | Moderate G6PD deficiency increases mutation rates in the brain of mice. Free Radical Biology and Medicine, 2002, 32, 663-673. | 2.9 | 20 |
| 52 | Prevalence and significance of sarcopenia in multiple myeloma patients undergoing autologous hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 225-231. | 2.4 | 17 |
| 53 | FOXM1 regulates glycolysis and energy production in multiple myeloma. Oncogene, 2022, 41, 3899-3911. | 5.9 | 16 |
| 54 | In a model of immunoglobulin heavyâ€chain (IGH)/MYCtranslocation, theIgh3â€² regulatory region inducesMYCexpression at the immature stage of B cell development. Genes Chromosomes and Cancer, 2007, 46, 950-959. | 2.8 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. Blood Cancer Journal, 2018, 8, 22. | 6.2 | 15 |
| 56 | Assessment of oxidative DNA damage in theoxyR-deficient sos chromotest straineschericia coli PQ300. Environmental and Molecular Mutagenesis, 1992, 20, 297-306. | 2.2 | 14 |
| 57 | Paradoxical decrease in mutant frequencies and chromosomal rearrangements in a transgenic lacZ reporter gene in Ku80 null mice deficient in DNA double strand break repair. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2003, 529, 51-58. | 1.0 | 14 |
| 58 | CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms. Molecular Cancer, 2006, 5, 22. | 19.2 | 14 |
| 59 | Coactivation of NF-Î²B and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion. Blood, 2020, 135, 108-120. | 1.4 | 14 |
| 60 | Jumping Translocation Breakpoint Regions Lead to Amplification of Rearranged Myc. Blood, 1999, 93, 4442-4444. | 1.4 | 13 |
| 61 | Suppression of steroid 5Î±-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma. Cell Death and Disease, 2021, 12, 206. | 6.3 | 13 |
| 62 | Identification of Candidate B-Lymphoma Genes by Cross-Species Gene Expression Profiling. PLoS ONE, 2013, 8, e76889. | 2.5 | 13 |
| 63 | Chromosomes 1 and 5 harbor plasmacytoma progressor genes in mice. Genes Chromosomes and Cancer, 2000, 29, 70-74. | 2.8 | 12 |
| 64 | CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma. Experimental Hematology and Oncology, 2015, 4, 9. | 5.0 | 12 |
| 65 | Non-Hodgkin Lymphomas of Mice. Blood Cells, Molecules, and Diseases, 2001, 27, 217-222. | 1.4 | 11 |
| 66 | Autonomic nervous system control of multiple myeloma. Blood Reviews, 2021, 46, 100741. | 5.7 | 11 |
| 67 | Uncovering MYC's full oncogenic potential in the hematopoietic system. Oncogene, 2005, 24, 3541-3543. | 5.9 | 10 |
| 68 | Germline Risk Contribution to Genomic Instability in Multiple Myeloma. Frontiers in Genetics, 2019, 10, 424. | 2.3 | 10 |
| 69 | Chronic intermittent hypoxia enhances disease progression in myeloma-resistant mice. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2019, 316, R678-R686. | 1.8 | 10 |
| 70 | TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. Journal of Clinical Investigation, 2021, 131, . | 8.2 | 10 |
| 71 | Translocation remodeling in the primary BALB/c plasmacytoma TEPC 3610. Genes Chromosomes and Cancer, 2001, 30, 283-291. | 2.8 | 9 |
| 72 | Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. BMC Genomics, 2007, 8, 302. | 2.8 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | WDR26 and MTF2 are therapeutic targets in multiple myeloma. Journal of Hematology and Oncology, 2021, 14, 203. | 17.0 | 8 |
| 74 | Extraosseous IL-6 transgenic mouse plasmacytoma sometimes lacksMyc-activating chromosomal translocation. Genes Chromosomes and Cancer, 2005, 43, 137-146. | 2.8 | 7 |
| 75 | Genetic and Environmental Cofactors of Myc Translocations in Plasma Cell Tumor Development in Mice. Journal of the National Cancer Institute Monographs, 2008, 2008, 37-40. | 2.1 | 7 |
| 76 | NIAM-Deficient Mice Are Predisposed to the Development of Proliferative Lesions including B-Cell Lymphomas. PLoS ONE, 2014, 9, e112126. | 2.5 | 7 |
| 77 | DNA sequence analysis of the genetIc recombination betweenIgh6 andMyc In an uncommon BALB/c plasmacytoma, TEPC 1194. Immunogenetics, 1996, 44, 151-156. | 2.4 | 6 |
| 78 | EÎ¼/SÎ¼ transposition into Myc is sometimes a precursor for T(12;15) translocation in mouse B cells. Oncogene, 2003, 22, 2842-2850. | 5.9 | 6 |
| 79 | Moderate Hypermutability of a Transgenic lacZ Reporter Gene in Myc-Dependent Inflammation-Induced Plasma Cell Tumors in Mice. Cancer Research, 2004, 64, 530-537. | 0.9 | 6 |
| 80 | Location ofMyc,Igh, andIgk on Robertsonian fusion chromosomes is inconsequential forMyc translocations and plasmacytoma development in mice, but Rb(6.15)-carrying tumors preferIgk-Myc inversions over translocations. Genes Chromosomes and Cancer, 2005, 42, 416-426. | 2.8 | 6 |
| 81 | Molecular and cytological features of the mouse B-cell lymphoma line iMycEmu-1. Molecular Cancer, 2005, 4, 40. | 19.2 | 6 |
| 82 | Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia. Blood, 2012, 119, 1018-1028. | 1.4 | 6 |
| 83 | Myeloma sleeper agent in myeloid disguise. Blood, 2019, 134, 3-4. | 1.4 | 6 |
| 84 | Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network metaâ€analysis of phase 3 randomized controlled trials. Cancer, 2020, 126, 2791-2801. | 4.1 | 6 |
| 85 | Isotype switch-mediatedCH deletions are a recurrent feature ofMyc/CH translocations in peritoneal plasmacytomas in mice. International Journal of Cancer, 2002, 101, 423-426. | 5.1 | 5 |
| 86 | A new model of LMP1â€“MYC interaction in B cell lymphoma. Leukemia and Lymphoma, 2014, 55, 2917-2923. | 1.3 | 5 |
| 87 | Elevated mutant frequencies in genelacI in splenic lipopolysaccharide blasts after exposure to activated phagocytesin vitro. European Journal of Immunology, 1997, 27, 2160-2164. | 2.9 | 4 |
| 88 | Overview of Mechanisms and Consequences of Chromosomal Translocation. Journal of the National Cancer Institute Monographs, 2008, 2008, 1-1. | 2.1 | 4 |
| 89 | Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma. Haematologica, 2020, 105, e111-e115. | 3.5 | 4 |
| 90 | Trends in the use of therapeutic plasma exchange in multiple myeloma. Journal of Clinical Apheresis, 2020, 35, 307-315. | 1.3 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma. Blood, 2021, 138, 2802-2802. | 1.4 | 4 |
| 92 | Transgenic Shuttle Vector Assays for Determining Genetic Differences in Oxidative B Cell Mutagenesis in Vivo. Methods in Enzymology, 2002, 353, 434-448. | 1.0 | 3 |
| 93 | Anaplastic plasmacytoma of mouseâ€"establishing parallels between subtypes of mouse and human plasma cell neoplasia. Journal of Pathology, 2010, 221, 242-247. | 4.5 | 3 |
| 94 | Mouse Models of Human Mature B-Cell and Plasma Cell Neoplasms. , 2008, , 179-225. | | 3 |
| 95 | Migration of Cells With Immunoglobulin/c-myc Recombinations in Lymphoid Tissues of Mice. Blood, 1997, 89, 291-296. | 1.4 | 3 |
| 96 | Critical Role for Cap-Independent c-MYC Translation in Progression of Multiple Myeloma. Molecular Cancer Therapeutics, 2022, 21, 502-510. | 4.1 | 3 |
| 97 | Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study. Blood Cancer Journal, 2022, 12, . | 6.2 | 3 |
| 98 | Bcl-2 reduces mutant rates in a transgenic lacZ reporter gene in mouse pre-B lymphocytes. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2003, 522, 135-144. | 1.0 | 2 |
| 99 | Laboratory Mice â€“ A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. Frontiers in Immunology, 2021, 12, 667054. | 4.8 | 2 |
| 100 | Evaluating the Antitumor Activity of MLN9708 in a Disseminated Mouse Model of Double Transgenic iMyc Ca/Bcl-XL Plasma Cell Malignancy.. Blood, 2009, 114, 3835-3835. | 1.4 | 2 |
| 101 | NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma. Blood, 2021, 138, 2671-2671. | 1.4 | 2 |
| 102 | Completion of the DNA sequence determination of the lgh2 locus of the mouse: the 5?-IA region. Immunogenetics, 1995, 43, 101-4. | 2.4 | 1 |
| 103 | Mouse model of MYD88L265P-dependent DLBCL. Blood, 2016, 127, 2660-2661. | 1.4 | 1 |
| 104 | MYC needs MNT to drive B cells over the edge. Blood, 2020, 135, 977-978. | 1.4 | 1 |
| 105 | MLN9708 Elicits Pharmacodynamic Response in the Bone Marrow Compartment and Has Strong Antitumor Activity in a Preclinical Intraosseous Model of Plasma Cell Malignancy.. Blood, 2009, 114, 1834-1834. | 1.4 | 1 |
| 106 | The Novel Proteasome Inhibitor MLN9708 Demonstrates Efficacy in a Genetically-Engineered Mouse Model of DeNovo Plasma Cell Malignancy.. Blood, 2009, 114, 3849-3849. | 1.4 | 1 |
| 107 | FOXM1, CDK6 and Rb Dependent Drug Resistance and Senescence in Myeloma. Blood, 2016, 128, 4456-4456. | 1.4 | 1 |
| 108 | Distinct MYC thresholds in hematopoietic neoplasia. Blood, 2006, 108, 413-413. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | TCL1-induced germinal center B lymphomas in mice. Blood, 2006, 108, 1791-1792. | 1.4 | 0 |
| 110 | Response to Guglielmi et al., â€œThe 3â€²IgH regulatory region is active at immature stages of Bâ€cell developmentâ€: Genes Chromosomes and Cancer, 2008, 47, 94-94. | 2.8 | 0 |
| 111 | New wrinkle on deubiquitination in B-cell lymphoma. Blood, 2018, 132, 2529-2530. | 1.4 | 0 |
| 112 | Dkk1 Transgenic Mice for the Study of Bone Lesions in Human Multiple Myeloma.. Blood, 2005, 106, 2505-2505. | 1.4 | 0 |
| 113 | IL-6 and Tumor Susceptibility Alleles of Strain BALB/C Cause Phenotypic Shift of MYC-Driven Lymphomas in Mice from Diffuse Large B-Cell Lymphoma (DLBCL) to Plasmacytoma (PCT). Blood, 2008, 112, 5316-5316. | 1.4 | 0 |
| 114 | Characteristics Associated with Disparities in Survival between Hispanic and Non-Hispanic White Patients with Multiple Myeloma: A Matched Cohort Study. Blood, 2021, 138, 4091-4091. | 1.4 | 0 |
| 115 | DNA sequence analysis of the genetic recombination between Igh6 and Myc in an uncommon BALB/c plasmacytoma, TEPC 1194. Immunogenetics, 1996, 44, 151-156. | 2.4 | 0 |